Developability Assessment – A Key Process to Derisk the Selection of ADC Clinical Candidates

Abzena’s VP of ADCs & Bioconjugates, Nicolas Camper, recently presented this poster at World ADC in San Diego.

Abstract

While identification of a lead candidate represents an important first step in the development of a novel ADC, broadly validating its design and mode of action, developability assessment is an equally important stage in the process of lead candidate optimization and clinical lead ADC selection.

Developability assessment aims to analyze ADC candidates through a range of assays evaluating their biological functionality, safety and manufacturability properties and detect any liability likely to impact their clinical performance or affect their ability to be manufactured successfully. Identification of liabilities provides areas to focus on for lead optimization and facilitates the selection of an optimal clinical lead.

Abzena applies a series of stage-appropriate experiments to systematically evaluate and optimize the properties of ADC candidates, ultimately allowing the selection of the best candidates for development with the greatest chance of clinical success.

Click Here to Access the Poster

Abzena poster authors include: Gavin Birch, Campbell Bunce, Nicolas Camper*, Judit Csapo, Grant Harradence, Arron Hearn, Rob Holgate, Erika Kovacs, Christopher Sayer